Cited by — Cost-effectiveness analysis of penpulimab plus anlotinib versus sorafenib as first-line therapy for advanced hepatocellular carcinoma | ResearchHub - ResearchHub

TikTok

Download ResearchHub

GET IT ONGoogle PlayComing soonDownload on theApp StoreComing soonEXPLORE IT ONAppGalleryComing soon

Research

Research Researchers Journals Institutions RHR Rankings

Contribute

Projects Questions Datasets Opportunities

Platform

ResearchHub platform About Blog Community Help API Licensing

Shopping

PDFHuB HubStor

Contact and support

Need help, have a question, or want to contact the ResearchHub team?

Contact and support support@aresearch.uk

Help Article feed Privacy Terms Cookies This work is licensed under Creative Commons Attribution 4.0 InternationalCC BY 4.0

Privacy-aware community infrastructure

Privacy & Cookies

We use cookies and similar technologies

ResearchHub uses necessary technologies for security, authentication and core functionality. Advertising choices, where available, are collected separately through Google's consent message.

See our Privacy Notice and Cookie Policy.

Research graph

Cited by

Admitted local publications that cite Cost-effectiveness analysis of penpulimab plus anlotinib versus sorafenib as first-line therapy for advanced hepatocellular carcinoma.

No admitted local citation edges point to this work yet.